6 October 2015 - - French medical device maker SpineGuard's 3Q revenue grew by 45% year-over-year, to EUR 1.6m, the company said on Tuesday.   SpineGuard said its global revenue in 3Q15 increased 45% to EUR 1.646m, compared with EUR 1.133m in 3Q14.

In the USA, the growth was 57% and 32% at constant exchange rate.

5,580 PediGuard units were sold in the first nine months of 2015 compared with 4,481 in the first nine months of 2014, including 3,064 in the United States, representing 55% of total units sold with a revenue increasing by 54% (26% cc) to EUR 3.647m compared with EUR 2.376m in the first nine months of 2014.

SpineGuard will participate in the Large and Midcap Event 2015 on October 7 and 8 in Paris. In addition, SpineGuard will participate in Actionaria on November 20 and 21 in Paris.

Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard's mission is to make spine surgery safer.

Its primary objective is to establish its proprietary DSG (Dynamic Surgical Guidance) technology as the global standard of surgical care, initially for safer screw placement in spine surgery and then in other surgeries.

PediGuard, the first device designed using DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

It is the world's first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 40,000 surgical procedures have been performed worldwide with PediGuard.

Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals.

In 2015, SpineGuard started to expand the applications of DSG into pedicle screws through partnerships with innovative surgical companies in France and the US. SpineGuard has offices in San Francisco and Paris.